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Threshold lung doses asso-
ciated with radiation pneu-
monitis (RP) are not well
established for patients
receiving modern medias-
tinal radiation for lymphoma.
This review found that 14%
of patients who received in-
tensity modulated radiation
therapy for lymphoma
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Hodgkin lymphoma (NHL), especially in patients treated with contemporary radiation
techniques. These patients represent a unique group owing to the often large radiation
target volumes within the mediastinum and to the potential to receive several lines of
chemotherapy that add to pulmonary toxicity for relapsed or refractory disease. Our
objective was to determine the incidence and clinical and dosimetric risk factors asso-
ciated with RP in lymphoma patients treated with intensity modulated radiation ther-
apy (IMRT) at a single institution.
Methods and Materials: We retrospectively reviewed clinical charts and radiation re-
cords of 150 consecutive patients who received mediastinal IMRT for HL and NHL
from 2009 through 2013. Clinical and dosimetric predictors associated with RP
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predicted RP risk, but low
doses to large lung volumes
was a particularly strong
predictor. Patients undergo-
ing salvage chemotherapy
for relapsed or refractory
disease who undergo peri-
transplant mediastinal RT are
at the greatest risk of RP.identified in univariate analysis using the Pearson c2 test and logistic multivariate
regression.
Results: Mediastinal radiation was administered as consolidation therapy in 110 pa-
tients with newly diagnosed HL or NHL and in 40 patients with relapsed or refractory
disease. The overall incidence of RP (RTOG grades 1-3) was 14% in the entire cohort.
Risk of RP was increased for patients who received radiation for relapsed or refractory
disease (25%) versus those who received consolidation therapy (10%, PZ.019).
Several dosimetric parameters predicted RP, including mean lung dose of >13.5 Gy,
V20 of >30%, V15 of >35%, V10 of >40%, and V5 of >55%. The likelihood ratio
c2 value was highest for V5 >55% (c
2 Z 19.37).
Conclusions: In using IMRT to treat mediastinal lymphoma, all dosimetric parameters
predicted RP, although small doses to large volumes of lung had the greatest influence.
Patients with relapsed or refractory lymphoma who received salvage chemotherapy
and hematopoietic stem cell transplantation were at higher risk for symptomatic RP.
 2015 The Authors. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Consolidative radiation after initial systemic therapy has
been shown to improve event-free survival rates in both
Hodgkin lymphoma and non-Hodgkin lymphoma (1-5).
Furthermore, for patients with relapsed or refractory disease,
radiation therapy (RT) can offer meaningful local disease
control (6, 7). An ongoing concern, however, is acute and
chronic toxicity related to RT. For patients with Hodgkin
lymphoma, most of whom receive bleomycin, concern has
been expressed about superimposing lung damage from ra-
diation on pulmonary toxicity from bleomycin.
Radiation pneumonitis (RP) is one of the main dose-
limiting toxicities among patients receiving thoracic RT.
Classic RP presents at 1 to 6 months after RT as a dry
cough, dyspnea (with exertion or at rest), low-grade fever,
and pleuritic chest pain. Often, evidence of damage within
the radiation field, such as ground glass opacities or con-
solidative change, appears on radiography. In mild cases
(ie, in Radiation Therapy Oncology Group [RTOG] grade 1
RP criteria), cough and dyspnea on exertion are mild and
self-limited (8). In more serious cases, severe cough and
dyspnea at rest can require steroid therapy (RTOG grade 3)
or continuous O2 therapy (RTOG grade 4).
Identification of dosimetric predictors of RP was
initially established in the treatment of nonesmall-cell lung
cancer, when Graham et al (9) reported the percentage of
lung volume receiving 20 Gy (V20) and the mean lung dose
(MLD) were correlated with RTOG grade 2 or higher RP in
99 patients treated with 3-dimensional (3D) conformal RT
(9). Numerous groups subsequently endorsed these findings
(10-12). Fewer publications, however, have addressed
whether lung dose-volume metrics can predict RP in
patients with lymphoma.
Koh et al (13) found a low incidence of RP of 3% among
64 patients with Hodgkin lymphoma who received involved-
field RT with 3D planning between 2003 and 2005. Theyidentified V20 of 36% and MLD of 14 Gy as predicting rates
of RTOG grade 2 RP exceeding 11%. Fox et al published the
largest study to date among patients with Hodgkin lym-
phoma treated to the mediastinum and found that MLD of
13.5 Gy or greater and V20 of 33.5% predicted RP in 92
patients treated with 3D conformal involved-field RT be-
tween 2003 and 2007 (14). Of particular interest was the
increased risk of more severe RP among peritransplantation
patients, 35% of whom had RTOG grade 3 RP.
As intensity modulated RT (IMRT) is increasingly being
used for patients with lung cancer, new dosimetric pre-
dictors of RP have emerged. The volume of lung that re-
ceives lower doses of radiation, such as 5 to 10 Gy, seems
to correlate more closely with risk of RP than conven-
tionally accepted V20 values (15, 16). To our knowledge, no
report of dosimetric predictors for RP among patients with
lymphoma who receive IMRT has been published. The
objective of the current study, therefore, was to determine
the incidence of RP among such patients and to review
clinical and radiation-dosimetric factors potentially asso-
ciated with the development of RP.
Methods and Materials
Patients
After approval by the appropriate institutional review board,
we identified 165 consecutive patients with Hodgkin or non-
Hodgkin lymphoma treated to themediastinumwith IMRTat
our institution between January 2009 and November 2013.
Fifteen of these patients were excluded for lack of follow-up,
leaving 150 for the current analysis. Clinical notes, radio-
graphic studies, laboratory results, and pulmonary function
test results were reviewed retrospectively. Pulmonary func-
tion testing was done immediately before RT in most cases.
Dose-volume histogram data were obtained from electronic
radiation treatment planning documents.
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Treatments were simulated while patients were immobi-
lized in the supine position with customized Vac-lock
cradles. Most female patients were positioned on a 10- to
15-inclined board to minimize dose to the breasts (17).
The breath-hold technique had been used only sporadically
before 2012 but was used routinely after 2012. For patients
who did not hold their breath during treatment planning, 4D
computed tomography (CT) was used to account for
respiration-induced motion of the target within the thorax.
For patients who achieved a complete response after
chemotherapy, radiation was delivered to involved sites
with the goal of targeting prechemotherapy sites of disease
involvement, with appropriate setup margin used according
to recent guidelines from the International Lymphoma
Radiation Oncology Group (18, 19). For patients with gross
disease at the time of radiation, the fields were more
generous and included the gross tumor and prophylactic
coverage of adjacent mediastinal nodal stations.
A commercial treatment planning system was used to
develop the IMRT plans. A 5-beam anterior-posterior
weighted “butterfly” beam arrangement was used for
treatment planning with coplanar 6-MV photon beams (20).
Tissue heterogeneity corrections were applied to the final
dose distribution. Normal structures, including the lungs,
were delineated on the planning simulation scan. The total
normal lung volume did not exclude the target gross tumor
volume, clinical target volume, or planning target volume
from the lung parenchyma. According to institutional
standards for treating the thorax for hematologic malig-
nancies, the pulmonary goals for planning were to keep the
MLD to <14 Gy, V20 to <35%, V10 to <50%, and V5 to
<60%. When these dosimetric constraints could not be
achieved, approval of the plan was at the discretion of the
treating physician. IMRTwas delivered with step-and-shoot
multileaf collimation. For most patients treated with breath-
hold technique to the mediastinum, 5 to 7 beams were used.
The average patient performed 20-second breath-holds
throughout the treatment. Each beam generally required 1
to 2 breath-holds to complete treatment for each field.
Image-guided RT was based on either daily kV imaging or
low-dose daily CT-on-rails (Varian Medical Systems, Palo
Alto, CA).Follow-up evaluations
Follow-up evaluations took place 1 to 3 months after
completion of RT and then at 3- to 6-month intervals
thereafter, with interval history and physical examination,
basic laboratory studies, and CT scans with or without
positron-emission tomography (PET)-CT.
RP was scored according to RTOG acute radiation
morbidity scoring criteria for pneumonitis (8). We consid-
ered all grades of RP to be significant. Charts were
reviewed by a board-certified radiation oncologist. Thediagnosis of RP was based on the appropriate clinical
symptoms with corresponding radiographic changes within
the radiation field occurring within 12 months of comple-
tion of radiation therapy without evidence of other
competing diagnoses (eg, infectious causes). The time to
RP was defined relative to the final day of RT.
Statistical analysis
We examined the following clinical factors for potential
association with RP: ethnicity, sex, age, lymphoma histol-
ogy, disease stage, axillary involvement requiring radiation,
type of initial chemotherapy (adriamycin, bleomycin,
vinblastine, dacarbazine [ABVD] vs other regimens),
number of chemotherapy cycles, number of bleomycin
cycles, history of bleomycin toxicity, history of salvage
chemotherapy before RT, peritransplant RT, bulky disease
(>10 cm), history of smoking, history of asthma or chronic
obstructive pulmonary disease (COPD), preradiation pul-
monary function test values, and use of breath-hold during
treatment. Dosimetric factors considered were total lung
dose, lung V25, V20, V15, V10, and V5, and MLD.
Pearson’s c2 test was used to assess measures of asso-
ciation in frequency tables. The equality of group medians
was assessed with nonparametric tests for equality.
Receiver operating characteristic (ROC) analysis and
logistic regression were done to assess whether dosimetric
factors could predict the development of RP. Threshold
doses for RP risk and doses corresponding to the optimal
point of the ROC curve were determined. Multivariate
logistic models identified independent predictors of pneu-
monitis. Additionally, individual logistic models, each
testing for a difference dosimetric parameter, were tested.
For each model, the likelihood ratio c2 values were ob-
tained and tested for significance against the baseline model
including all covariates except the dosimetric parameter.
P values of .05 were considered statistically significant.
Statistical tests were based on a 2-sided significance level.
All data analyses were done with Stata/MP version 13.0
software (StataCorp, College Station, TX).
Results
Characteristics of the 150 patients included in the study are
listed in Table 1, and treatment details are shown in
Table 2. Of 150 patients, 40 had relapsed or refractory
disease and received salvage chemotherapy. Of these 40
patients, 37 underwent autologous stem cell transplantation
(nZ30) or allogeneic stem cell transplantation (nZ6) or
both (nZ1).
Twenty-one patients (14% of the entire group) devel-
oped pneumonitis at a median 2.04 months after comple-
tion of RT (range: 0.33-9.18 months). RP was grade 1 in 9
cases, grade 2 in 2 cases, and grade 3 in 10 cases (Table 3).
No patient had grade 4 or 5 RP. The incidence of severe
(grade 3) RP was 6.7% for all patients. Among the 110
Table 1 Baseline characteristics of 150 patients who
received mediastinal radiation therapy for Hodgkin or non-
Hodgkin lymphoma
Characteristic Value or no. of patients (%)
Age
Median, years (range) 33.0 (16.6-78.1)
Sex
Female 88 (58.7)
Male 62 (41.3)
Ethnicity
White 109 (72.7)
African-American 12 (8.0)
Hispanic 18 (12.0)
Asian 5 (3.3)
Other 6 (4.0)
Tumor histology
Hodgkin lymphoma 110 (73.3)
Non-Hodgkin lymphoma 40 (26.7)
Disease stage
I 16 (10.7)
II 106 (70.7)
III 11 (7.3)
IV 17 (11.3)
Bulky disease (>10 cm)
Yes 87 (58)
No 63 (42)
Smoking history
Yes 36 (24)
No 114 (76)
Asthma/COPD
Yes 7 (4.7)
No 143 (95.3)
% of pre-RT FVC
Median 94.0
Range 45-136
% of pre-RT FEV1
Median 94.5
Range 28-134
% of corrected pre-RT
DLCO, corrected
Median 81.5
Range 31-130
Abbreviations: COPD Z chronic obstructive pulmonary disease;
pre-RT DLCO Z preradiation diffusion lung capacity for carbon
monoxide; Pre-RT FEV1 Z preradiation forced expiratory volume in
1 second; Pre-RT FVC Z preradiation forced vital capacity.
Table 2 Treatment characteristics for 150 patients given
mediastinal radiation therapy for Hodgkin or non-Hodgkin
lymphoma
Characteristic Value or no. of patients (%)
ABVD
Yes 109 (72.7)
No 41 (27.3)
Cycles of chemotherapy
Median (range) 6 (0-8.5)
Cycles of Bleomycin
Median (range) 4 (0-8.5)
Bleomycin toxicity
Yes 17 (11.3)
No 133 (88.7)
Salvage chemotherapy pre-RT
Yes 40 (26.7)
No 110 (73.3)
Transplant
Yes 37 (24.7)
Autologous 30
Allogeneic 6
Both 1
No 113 (75)
RT before transplant 13 (35)
RT after transplant 24 (64.9)
Radiation dose
Median 30.6
Range 20-44.6
30.6 Gy 90
>30.6 Gy 60
Axilla treated
Yes 23 (15.3)
No 127 (84.7)
Breathhold
Yes 70 (46.7)
No 80 (53.3)
V25
Median (range) 18 (0-34)
V20
Median (range) 24 (4-40)
V15
Median (range) 30.0 (10-45)
V10
Median (range) 37.0 (15-59)
V5
Median (range) 50 (23-66)
Mean lung dose
Median (range) 10.6 (3.8-16.3)
Abbreviation: ABVD Z doxorubicin, bleomycin, vinblastine,
dacarbazine.
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initial chemotherapy, the incidence of any RP was 10%.
Among the 40 patients with relapsed or refractory disease
who received salvage chemotherapy, the incidence of RP
was significantly higher at 25% (PZ.019).
For the 21 patients who developed RP, the median MLD
was 12.9 Gy (range: 8.2-16.3 Gy) compared with 10.3 Gy
(range: 3.8-16.0 Gy) among patients who did not develop
RP. The corresponding V5 was 58% for those who had RP
(range: 38%-66%) versus 49% for those who did not
(range: 23%-64%). Other dosimetric parameters analyzed
are listed in Table 4.Dosimetric and clinical factors potentially predictive of
RP are listed in Table 5. For all dosimetric parameters
examined (V25, V20, V15, V10, V5, and MLD), cutoff values
were identified that were significantly associated with RP.
ROC were generated to identify the predictive abilities of
the dosimetric variables found to be significant on paired t
tests by using the areas under the ROC. Based on these
Table 3 Radiation pneumonitis according to the purpose of
radiation therapy
Pneumonitis
No. of patients (%)
All patients
(nZ150)
Consolidative
RT patients
(nZ110)
Patients with
relapsed or refractory
disease (nZ40)
None 129 (86) 99 (90) 30 (75)
Any 21 (14) 11 (10) 10 (25)
Grade 1 9 (6) 6 (5.5) 3 (7.5)
Grade 2 2 (1.3) 0 (0) 2 (5.0)
Grade 3 10 (6.7) 5 (4.5) 5 (12.5)
Table 5 Clinical and dosimetric factors potentially associ-
ated with radiation pneumonitis
Factor*
No. of patients (%)
Patients
with no
pneumonitis
(nZ129)
Patients
with any
pneumonitis
(nZ21) P value
Mean lung dose
>12 Gy 34 (26.4) 12 (57.1) .005
>13 Gy 17 (13.2) 10 (47.6) <.001
>13.5 Gy 9 (7.0) 9 (42.9) <.001
>14 Gy 5 (3.9) 6 (28.6) <.001
V5
>50% 49 (38.0) 15 (71.4) .004
>55% 26 (20.2) 14 (66.7) <.001
>60% 10 (7.8) 5 (23.8) .023
V10
>30% 94 (72.9) 20 (95.2) .026
>35% 66 (51.2) 16 (76.2) .033
>40% 34 (26.4) 13 (61.9) .001
>45% 12 (9.3) 7 (33.3) .002
V15
>25% 83 (64.3) 20 (95.2) .005
>30% 54 (41.9) 15 (71.4) .012
>35% 23 (17.8) 11 (52.4) .001
>40% 5 (3.9) 2 (9.5) .255
V20
>25% 52 (40.3) 13 (61.9) .064
>30% 15 (11.6) 8 (38.1) .002
>33% 8 (6.2) 5 (23.8) .008
>35% 3 (2.3) 2 (9.5) .088
V25
>20% 46 (35.7) 13 (61.9) .022
>23% 28 (21.7) 12 (57.1) .001
>25% 13 (10.1) 7 (33.3) .004
History of bleomycin
toxicity
16 (12.4) 1 (4.8) .306
History of smoking 28 (21.7) 8 (38.1) .103
Bulky disease (>10.0 cm) 75 (58.1) 12 (57.1) .932
Relapsed or refractory
disease
30 (23.2) 10 (47.6) .019
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dosimetric parameters were identified as being significantly
associated with the development of any RP (grades 1-3):
MLD of 13.5 Gy (P<.001), V25 of >23% (PZ.001), V20
of >30% (PZ.002), V15 of 35% (P<.001), V10 of 40%
(PZ.001), and V5 of 55% (P<.001). RP developed in 9
of 18 patients (50%) with an MLD of >13.5 Gy versus 12
of 130 patients (9.2%) with an MLD of 13.5 Gy; 12 of 40
patients (30%) with V25 of >23% versus 9 of 110 patients
(8.2%) with V25 of <23%; 8 of 23 patients (34.8%) with
V20 of >30% versus 13 of 127 patients (1.2%) with V20 of
<30%; 11 of 34 patients (32.4%) with V15 of <35% versus
10 of 116 patients (8.6%) with V15 of <35%; 13 of 47
patients (27.7%) with V10 of >40% versus 8 of 103 patients
(7.8%) with V10 <40%; and 14 of 40 patients (35%) with
V5 of >55% versus 7 of 110 patients (7.0%) with V5
<55%. The only clinical factors found to predict the
development of RP was history of relapsed or refractory
disease, for which transplantation or salvage chemotherapy
(or both) was given. Race, disease stage, sex, age, type of
chemotherapy, number of chemotherapy cycles, history of
bleomycin toxicity, disease bulk, history of smoking, his-
tory of asthma or COPD, and pre-RT pulmonary function
test values did not predict RP (Table 5). Among the patients
who received peritransplant RT, no significant differencesTable 4 Dosimetric predictors of radiation pneumonitis
Parameter
No
pneumonitis
Any
pneumonitis
P
value
Mean lung dose, Gy
Median (range) 10.3 (3.8-16.0) 12.9 (8.9-16.3) .018
% receiving V25
Median (range) 18.0 (0-34) 24.0 (14-32) .254
% receiving V20
Median (range) 23.0 (4-40) 30.0 (20-37) .228
% receiving V15
Median (range) 28.0 (10-45) 36.0 (23-43) .022
% receiving V10
Median (range) 36.0 (15-59) 44.0 (28-51) .051
% receiving V5
Median (range) 49.0 (23-64) 58.0 (38-66) .008
Use of breathhold 60 (46.5) 10 (47.6) .925
Peritransplant radiation 28 (21.7) 9 (42.9) .037
Before transplant 9 (69.2) 5 (20.8) .501
After transplant 19 (79.2) 4 (30.8)
* Factors in boldface type represent the most significant cutoff
points for RP according to receiver operating characteristic curves.were found between rates of RP for patients who received
RT before or after transplantation (PZ.501) (Table 5). On
logistic regression, dosimetric dose-volume and MLD pa-
rameters remained significant (Table 6). History of salvage
chemotherapy (odds ratio [OR] Z 3.00, 95% confidence
interval [CI]: 1.16-7.75, PZ.023) and transplantation (OR
Z 2.71, 95% CI: 1.04-7.07, PZ.042) remained indepen-
dent predictors of RP on univariate analysis.
In separate multivariate models testing each possible
dosimetric threshold, every cutoff from V5 to V25 was
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largest for the model including the V5 dosimetric factor,
where V5 was >55% (likelihood ratio c
2 Z 19.37), high-
lighting the strength of this dosimetric parameter for pre-
dicting the variance in pneumonitis risk (Table E1;
available online at www.redjournal.com). MLD was also aTable 6 Univariate analysis of potential clinical and dosi-
metric factors associated with radiation pneumonitis
Parameter Odds ratio 95% CI P value
Mean lung dose
Continuous 1.46 1.17-1.83 .001
>12 Gy 1.91 1.19-3.07 .008
>13 Gy 2.43 1.47-3.99 <.001
>13.5 Gy 3.14 1.81-5.43 <.001
>14 Gy 3.12 1.63-5.99 .001
V5
Continuous 1.12 1.05-1.20 .001
>50% 4.08 1.48-11.22 .006
>55% 7.92 2.90-21.63 <.001
>60% 3.72 1.13-12.27 .031
V10
Continuous 1.12 1.04-1.20 .002
>35% 3.05 1.06-8.83 .039
>40% 4.54 1.73-11.90 .002
>45% 4.88 1.65-14.42 .004
V15
Continuous 1.13 1.05-1.22 .002
>25% 11.08 1.44-85.28 .021
>30% 3.47 1.27-9.53 .016
>35% 5.07 1.93-13.34 .001
>40% 2.61 0.47-14.43 .271
V20
Continuous 1.12 1.03-1.21 .005
>25% 2.41 0.93-6.21 .07
>30% 4.68 1.67-13.13 .003
>33% 4.73 1.38-16.22 .014
>35% 4.42 0.69-28.20 .116
V25
Continuous 1.12 1.03-1.21 .005
>20% 2.93 1.13-7.59 .027
>23% 4.81 1.84-12.56 .001
>25% 4.46 1.53-13.05 .006
Pre-RT FVC 1.00 0.97-1.03 .999
Pre-RT FEV1 1.00 0.97-1.03 .882
Pre-RT DLCO (corrected) 1.00 0.96-1.03 .869
Radiation dose
Continuous 1.13 1.03-1.24 .012
>30.6 Gy 2.19 0.86-5.59 .1
History of bleomycin toxicity 0.35 0.04-2.81 .326
History of smoking 2.22 0.84-5.89 .109
Bulky disease (>10.0 cm) 0.96 0.38-2.44 .932
Relapsed/refractory disease 3.00 1.16-7.75 .023
Use of breath-hold 1.05 0.42-2.63 .925
Peritransplant RT 2.71 1.04-7.07 .042
Abbreviations: Pre-RT DLCO Z pre-radiation diffusion lung
capacity for carbon monoxide; Pre-RT FEV1 Z pre-radiation forced
expiratory volume in 1 second; Pre-RT FVC Z pre-radiation forced
vital capacity.strong predictor (likelihood ratio c2 Z 15.17). In contrast,
the lowest likelihood ratio c2 value was for V20 of >30%
(likelihood ratio c2 Z 8.33).Discussion
To our knowledge, this is the first study to specifically
examine the incidence of and risk factors associated with
the development of RP among patients with lymphoma
treated with IMRT. The overall incidence of any RP (RTOG
grades 1-3) was 14% among the entire group. However,
patients who received salvage chemotherapy or trans-
plantation for relapsed or refractory disease were at greater
risk: the incidence of RP among those patients was 25%
versus 10% among those who received consolidative RT for
newly diagnosed disease. These numbers are strikingly
similar to the incidence of RP in a large series of patients
treated with anterior-posterior 3D conformal RT for
Hodgkin lymphoma reported by Fox et al (14). In their
study, RP developed in 14% of patients (13 of 92 patients),
10% for those with newly diagnosed disease versus 35% for
those with relapsed and refractory lymphoma who received
peritransplantation RT. These findings suggest that the risk
of RP is greatest in patients treated for relapsed and re-
fractory disease, and the overall risk of RP is comparable.
However in the current series, we observed higher rates of
grade 3 RP among patients who were treated with con-
solidative IMRT after initial chemotherapy. In the series by
Fox et al (14), only 1 of 75 patients with newly diagnosed
disease (1.3%) developed grade 3 RP compared to 5 of 110
patients in our study (4.5%). This suggests that when IMRT
is used in this setting, even despite the use of low to
moderate prescription doses, close adherence to pulmonary
dose constraints should be maintained to limit the potential
for grade 3 toxicity. Conversely, the rate of grade 3 RP was
higher among relapsed and refractory patients treated with
3D conformal RT (4 of 17 patients [23.5%]) compared with
IMRT in the current study (5 of 40 patients [12.5%]).
This may be partially explained by the need to escalate
doses in this patient population and the enhanced ability to
modulate higher RT doses out of normal pulmonary tissue
with IMRT.
In contrast to 3D conformal RT, distinct dosimetric pa-
rameters should be considered in IMRT planning and plan
assessment. For patients treated with 3D conformal RT, the
volume of lung receiving 20 Gy has consistently been
found to predict the risk of symptomatic RP. In the study by
Fox et al (14), a V20 of 33.5% was the threshold value. Koh
et al (13) found that a V20 of 36% predicted RP among 64
patients with Hodgkin lymphoma who received 3D
conformal RT to the thorax. Similarly, another study found
that the volume of lung receiving 20 Gy predicted RP risk
among 99 pediatric patients with Hodgkin lymphoma
treated with 3D conformal RT (21). In the current study, in
which IMRT was used exclusively for RT delivery, the V20
did predict RP risk; however, the volume of lung receiving
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powerful predictor of RP. This finding has been endorsed in
other studies evaluating the ability of dosimetric parameters
to predict RP in the treatment of primary lung cancer with
IMRT (15, 16). This result may reflect the conformality of
the higher doses of radiation, in which the lower volumes
being exposed to high doses become less clinically rele-
vant. In turn, increases in the volume of lung that receives
lower doses becomes more clinically meaningful with re-
gard to pulmonary injury. This mechanism of lung damage
would not be evident in patients treated with anterior-
posterior 3D conformal RT plans because the volume of
lung that would receive 5 Gy is typically no higher than the
volume that receives 20 Gy. Therefore, from a clinical
standpoint, evaluation of IMRT plans to the mediastinum
must carefully consider not only the volume of lung
receiving higher doses of radiation, because the V25, V20,
and MLD were also predictive of RP in our patients, but
also lower doses. Indeed, Fox et al (14) reported that an
MLD of >13.5 Gy predicted RP, a finding consistent with
the current study.
Use of IMRT in Hodgkin lymphoma has been ques-
tioned because of concern for the low-dose bath associated
with use of multiple IMRT beams in a concentric beam
arrangement. This raises concern for an increase in risk of
secondary malignancy, particularly for young patients who
often have an excellent long-term prognosis. To mitigate
this concern, we used an anterior-posterior weighted IMRT
beam arrangement with limited numbers of beams (typi-
cally 5) (20). This practice allows additional conformality
around critical cardiac structures (the coronary arteries and
left ventricle in particular) while it minimizes the low-dose
exposure to the uninvolved thorax. We also used a breath-
hold technique to minimize respiration-based motion and
reduce lung exposure to radiation, although in this study,
use of breath-hold was not associated with reduced risk of
RP (22-24).
Bleomycin-induced lung injury requiring cessation of
this drug is not uncommon among patients with Hodgkin
lymphoma (25-27). Concern has been expressed about the
safety of mediastinal RT after bleomycin pulmonary
toxicity; however, we did not find RP to be associated with
a history of bleomycin toxicity. Our findings endorses those
of previous studies that mediastinal RT is not contra-
indicated after bleomycin lung injury (14, 28).
The risk of pneumonitis among patients who receive
salvage chemotherapy and peritransplantation RT should
not be taken lightly. High-dose chemotherapy followed by
hematopoietic stem cell transplantation is associated with
an inherent risk of pneumonitis, even in the absence of
thoracic RT (29, 30). However, when peritransplantation
RT is administered, the risk of pneumonitis increases, as
shown in several studies (14, 31-33). One such study
showed that RT given in the pretransplantation setting
increased mortality among patients with Hodgkin lym-
phoma (33). Another group found that pretransplantation
RT was significantly associated with grade 3 RP (57% vs0% for post-transplantation RT, PZ.015) (14). No patient
in either of these 2 series experienced fatal RP. At our
institution, preferred practice is for RT to be given after a
stem cell transplantation; however, in circumstances where
disease control cannot be achieved with salvage chemo-
therapy, RT is given before transplantation. Indeed, in the
current study, RT was given before transplantation to 13
patients (35%) and after transplantation to 24 patients
(74.9%). Overall, peritransplantation RT was associated
with increased risk of RP (RP rate of 24% in peri-
transplantation patients vs 10.6% in newly diagnosed pa-
tients), but no differences in RP were found between
patients who received RT before versus those who received
transplantation afterward. The increased overall risk for RP
among patients with relapsed or refractory disease high-
lights the need to carefully scrutinize IMRT plans to be
given to patients receiving RT after salvage chemotherapy
and in the peritransplantation period. It is plausible that a
history of salvage chemotherapy alone, in the absence of
transplantation, independently increases the risk relative to
the transplant; however, we could not evaluate this point in
the current study because almost all patients who received
salvage chemotherapy went on to undergo autologous or
allogeneic stem cell transplantation. Also important is that
in the current study, the lung volume used did not exclude
any target volumes, a point to be considered if the threshold
values identified in this report are used.
Conclusions
In conclusion, MLD and low-dose parameters such as V5,
V10, and V15 are valuable predictors for the development of
RP in patients with lymphoma treated with IMRT. Patients
with relapsed or refractory disease who receive salvage
chemotherapy and undergo hematopoietic stem cell trans-
plantation are at particularly high risk of RP. Regardless,
when >55% of the total lung receives 5 Gy in the treatment
of Hodgkin or non-Hodgkin lymphoma with IMRT, the risk
of RP approaches 35%.References
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